fbpx

Pipeline

PRODUCT CANDIDATES

PLUS THERAPEUTICS is focused on developing innovative, targeted radiotherapeutics for adult and pediatric patients worldwide with rare and difficult-to-treat cancers. These are incurable and often fatal diseases for which there are few good treatment options. PLUS THERAPEUTICS is looking to offer novel treatments with potentially improved safety, efficacy, and convenience to these patients and their healthcare providers.

Our lead product candidate, 186RNL (BMEDA-Chelated Rhenium-186 NanoLiposome) is designed and intended to treat various central nervous system (CNS) tumors. 

186RNL

Central Nervous System (CNS) Tumors

DEVELOPMENT STATUS

Our pipeline is founded upon promising data generated in a variety of preclinical studies and company-sponsored clinical trials.

186RNL (BMEDA-Chelated Rhenium-186 NanoLiposome)

Indication
Delivery
Designations
Funding
Status
Recurrent GlioblastomaIntratumoral+ FDA Orphan Drug
+ FDA Fast Track
NIH/NCIReSPECT-GBM Phase 1 Clinical Trial (Enrolling)
Leptomeningeal MetastasesIntrathecal
-
-
ReSPECT-LM Phase 1 Clinical Trial (Pre-FDA IND)
Pediatric Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG)Intratumoral
-
-
ReSPECT-PBC Phase 1 Clinical Trial (Pre-FDA IND)
Pediatric Recurrent Ependymoma
Intratumoral
-
-
ReSPECT-PBC Phase 1 Clinical Trial (Pre-FDA IND)
Pediatric Recurrent High-Grade Glioma (HGG)Intratumoral
-
-
ReSPECT-PBC Phase 1 Clinical Trial (Pre-FDA IND)
Peritoneal CarcinomatosisIntraperitoneal
-
-
Late-Stage Preclinical
Head & Neck Squamous Cell CarcinomaIntratumoral
-
-
Late-Stage Preclinical

PLUS THERAPEUTICS has an open FDA-approved IND and an active, enrolling, U.S. multi-center NIH-supported Phase 1/2 clinical trial of 186RNL for patients with recurrent glioblastoma. To learn more about 186RNL, click here.  To learn more about the ReSPECT™-GBM Clinical Trial, click here.